# Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

> **NCT05644262** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 120 (estimated)

## Conditions studied

- Agitation
- Dementia

## Interventions

- **DRUG:** T2:C100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05644262
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-08-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644262, "Life's End Benefits of cannaBidiol and tetrahYdrocannabinol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05644262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*